Brief: Revive Therapeutics Expects To Engage Up To 10 Clinical Trial Sites In U.S.
05/08/2020 15:09
Aug 5 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS UPDATE FOLLOWING U.S. FDA APPROVAL OF
PHASE
3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - EXPECTS TO ENGAGE UP TO 10
CLINICAL
TRIAL SITES IN U.S. AND OPEN PHASE 3 CLINICAL TRIAL FOR PATIENT
SCREENING IN Q3
* REVIVE THERAPEUTICS LTD - FINALIZING VENDOR AGREEMENTS IN
PROJECT MANAGEMENT, MEDICAL MONITORING
Source text for Eikon: ID:nGNXbH3lhV
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure